This inventor holds 1 USPTO granted patent. Top assignees: Alfact Innovation, National Institute of Health and Medical Research, Université Paris Diderot-Paris 7. Active years: 2017.
Company Filing History:
1 out of 2 
1 out of 1,853 
1 out of 111 
Years Active: 2017
Title: Jamila Vaivre: Innovator in Insulin Resistance Treatment
Introduction
Jamila Vaivre is a prominent inventor based in Paris, France. She has made significant contributions to the field of medical research, particularly in the treatment of insulin resistance. Her innovative work has led to the development of a unique patent that addresses a critical health issue.
Latest Patents
Jamila Vaivre holds a patent for a composition that includes the HIP/PAP protein or its derivatives for treating insulin resistance. This invention is particularly relevant for non-insulin dependent subjects, providing a potential solution for managing this condition effectively. The patent highlights her commitment to advancing medical science and improving patient outcomes.
Career Highlights
Throughout her career, Jamila has worked with notable organizations such as Alfact Innovation and the National Institute of Health and Medical Research. Her experience in these institutions has allowed her to collaborate with leading experts in the field, further enhancing her research capabilities and impact.
Collaborations
Jamila has collaborated with esteemed colleagues, including Fabrizio Andreelli and Paul Amouyal. These partnerships have played a crucial role in her research endeavors, fostering an environment of innovation and shared knowledge.
Conclusion
Jamila Vaivre's contributions to the field of insulin resistance treatment exemplify her dedication to medical innovation. Her patent and collaborative efforts reflect her significant role in advancing healthcare solutions.